Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Johnson Chemical Pharmaceutical Works Co Debt-to-EBITDA Related Terms
Johnson Chemical Pharmaceutical Works Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson Chemical Pharmaceutical Works Co Debt-to-EBITDA Chart
Johnson Chemical Pharmaceutical Works Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Johnson Chemical Pharmaceutical Works Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson Chemical Pharmaceutical Works Co Debt-to-EBITDA vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Johnson Chemical Pharmaceutical Works Co (ROCO:4747) has a Debt-to-EBITDA of 7.15 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Johnson Chemical Pharmaceutical Works Co. This is 496% above median its historical median of 1.20. Over the past decade, Johnson Chemical Pharmaceutical Works Co's Debt-to-EBITDA has ranged from 0.60 to 5.14. According to the industry distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #560 out of 678 companies in the Drug Manufacturers industry, placing it in the top 82.6%.
Is Johnson Chemical Pharmaceutical Works Co's Debt-to-EBITDA too high?
Johnson Chemical Pharmaceutical Works Co's current Debt-to-EBITDA of 7.15 is 496% above median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 5.14. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Johnson Chemical Pharmaceutical Works Co's value of 7.15 is 336% above this industry median. Based on the distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #560 out of 678 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Johnson Chemical Pharmaceutical Works Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Johnson Chemical Pharmaceutical Works Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Johnson Chemical Pharmaceutical Works Co ranks #560 out of 678 companies for Debt-to-EBITDA. This places Johnson Chemical Pharmaceutical Works Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Johnson Chemical Pharmaceutical Works Co's value of 7.15 is 336% above this benchmark. Historically, Johnson Chemical Pharmaceutical Works Co's own Debt-to-EBITDA has ranged from 0.60 to 5.14 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 1.64, Johnson Chemical Pharmaceutical Works Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Johnson Chemical Pharmaceutical Works Co's current Debt-to-EBITDA of 7.15 is 336% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Johnson Chemical Pharmaceutical Works Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Johnson Chemical Pharmaceutical Works Co's current Debt-to-EBITDA is 7.15, which is 496% above median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson Chemical Pharmaceutical Works Co stock overvalued right now?
Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co (ROCO:4747) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$31.30, compared to a current price of NT$28.25 — trading 9.7% below its estimated fair value. The current Debt-to-EBITDA is 7.15, which is 496% above median its 10-year median of 1.20 and 336% above the Drug Manufacturers industry median of 1.64. Johnson Chemical Pharmaceutical Works Co's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Johnson Chemical Pharmaceutical Works Co (ROCO:4747), the current Debt-to-EBITDA is 7.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Johnson Chemical Pharmaceutical Works Co (ROCO:4747) Overvalued in 2026?
Based on GuruFocus' analysis, Johnson Chemical Pharmaceutical Works Co stock appears to be undervalued.
The current stock price of NT$28.25 is trading 9.7% below its estimated GF Value™ of NT$31.30.
GuruFocus considers Johnson Chemical Pharmaceutical Works Co to be Modestly Undervalued.
Key valuation signals for ROCO:4747:
Debt-to-EBITDA: 7.15 (496% above median its 10-year median of 1.20)
GF Value™: NT$31.30 vs. price of NT$28.25 (9.7% below fair value)
Industry Position: 336% above the Drug Manufacturers median (#560 of 678)
No single metric tells the full story. See the ROCO:4747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Johnson Chemical Pharmaceutical Works Co is engaged in the manufacturing of pharmaceutical ingredients, importing and selling pharmaceutical materials and products. It manufactures drugs in a variety of forms, including solid dosage forms, capsules (soft/hard), tablets (sugar/film-coated), powder and granule, as well as nasal sprays. It offers products in therapeutic areas including the central nervous system, respiratory, cardiovascular, gastrointestinal, and endocrine system, vitamins, anti-inflammatory, cough and cold, and pain relievers. Its revenue mainly comes from medical product sales.
72GF Score
Get the complete analysis for ROCO:4747
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4747 has been successfully added to your 
